ClinicalTrials.gg
CompletedNCT04072146Updated May 23, 2022Results posted

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

A Phase 1 interventional study of Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg and OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg in Healthy Subjects, sponsored by Oyster Point Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-23.

Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To assess the relative bioavailability of varenicline administered intranasally at its highest intended clinical strength compared to varenicline administered orally at its highest oral tablet strength.

Read the detailed description

This study was a Phase 1, open-label, randomized, 2-way crossover study to evaluate the relative bioavailability of OC-01 (varenicline) Nasal Spray compared to varenicline administered orally as varenicline oral tablet. Approximately 22 healthy volunteer subjects between 18-65 years of age meeting all other study eligibility criteria were randomized (Treatment Period 1) to receive an intranasal dose of 0.12 mg OC-01 (50 µL spray of 0.06 mg into each nostril) or a single 1 mg oral dose of varenicline oral tablet. Both administrations were delivered while subject is in an overnight fasted state. Subjects then returned at least 14 days later (Treatment Period 2) to receive the alternate dose of varenicline that was delivered at Treatment Period 1. Again, this delivery was performed while subject was in an overnight fasted state.

Participants who terminated early during the application period were asked to complete safety assessments (if the participants agree) prior to study exit. Participants who were terminated early from the study were not replaced.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Oyster Point Pharma, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18.0 and 32.0 kg/m2, inclusive.
  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, and laboratory tests.
  • Have provided verbal and written
  • If a female of who is not using an acceptable means of (acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives, mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom, IUD, or surgical sterilization of partner), have a negative urine pregnancy test at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • Have had nasal or sinus surgery (including history of application of nasal cautery) or significant trauma to these areas.
  • Have a vascularized polyp, severely deviated septum, chronic recurrent nosebleeds, or severe nasal airway obstruction as confirmed by intranasal examination at the Screening Visit.
  • Any to varenicline according to the applicable label.
  • Have severe renal impairment (estimated less than 30mL per minute)
  • Have current concomitant use of snuff, chewing tobacco, e-cigarettes or cigarettes/cigars during the study
  • Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject
  • Be a female who is pregnant, nursing an infant, or planning a pregnancy at the Screening Visit. Be a woman of who is not using an acceptable means of ; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner.
  • Be currently enrolled in an drug or device study or have used an investigational drug or device within 30 days prior to the Screening Visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Varenicline oral tablet 1mg, then OC-01 (varenicline solution) nasal spray 0.12 mg

    OC-01 0.12 mg was administered intranasally 50 ul into each nostril in a fasted state

    Drug: Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg

  • Active comparator
    OC-01 (varenicline solution) nasal spray 0.12 mg, then Varenicline oral tablet 1 mg

    Varenicline oral tablet 1mg was administered orally in a fasted stated with 200 ml water

    Drug: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area under the curve from predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

    Time frame: Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

  2. AUC0-inf

    AUC0-inf taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

    Time frame: Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

  3. Cmax

    Cmax taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

    Time frame: Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

  4. Tmax

    Tmax taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

    Time frame: Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

Other outcomes

  1. Creatine Shift From Normal at Baseline to Abnormal After 2 Hours Post-treatment

    Creatine shift from baseline to 2 hours post treatment. Elevated creatinine may indicate impaired kidney function.

    Time frame: Baseline to 2 hours post treatment

07

Results

Posted May 23, 2022

Participant flow

Participant flow — Overall Study
MilestoneVarenicline Oral Tablet 1 mg, Then OC-01 (Varenicline) Nasal 0.12 mgOC-01 (Varenicline Solution) Nasal Spray 0.12 mg, Then Varenicline Oral Tablet 1 mg
Started1111
Completed1110
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryAUC0-t

Area under the curve from predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

Time frame:
Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Reported as:
Mean · h*ng/ml
AUC0-t
h*ng/mlVarenicline Oral Tablet 1 mgOC-01 (Varenicline) Nasal Spray 0.12 mg
AUC0-t4.49 ± 3.4298.74 ± 25.49
PrimaryAUC0-inf

AUC0-inf taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

Time frame:
Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Reported as:
Mean · h*ng/mL
AUC0-inf
h*ng/mLOC-01 (Varenicline) Nasal Spray 0.12 mgVarenicline Oral Tablet 1 mg
AUC0-inf8.3 ± 4.09102.83 ± 16.82
PrimaryCmax

Cmax taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

Time frame:
Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Reported as:
Mean · ng/ml
Cmax
ng/mlOC-01 (Varenicline) Nasal Spray 0.12 mgVarenicline Oral Tablet 1 mg
Cmax0.34 ± 0.134.63 ± 0.93
PrimaryTmax

Tmax taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.

Time frame:
Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Reported as:
Median · h
Tmax
hOC-01 (Varenicline) Nasal Spray 0.12 mgVarenicline Oral Tablet 1 mg
Tmax2.0 (0.3 to 3.0)3 (1 to 6)
Other pre-specifiedCreatine Shift From Normal at Baseline to Abnormal After 2 Hours Post-treatment

Creatine shift from baseline to 2 hours post treatment. Elevated creatinine may indicate impaired kidney function.

Time frame:
Baseline to 2 hours post treatment
Reported as:
Count of participants · Participants
Creatine Shift From Normal at Baseline to Abnormal After 2 Hours Post-treatment
ParticipantsVarenicline Oral Tablet 1mg, Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mgOC-01 (Varenicline Solution) Nasal Spray 0.12 mg, Then Varenicline Oral Tablet 1 mg
Creatine Shift From Normal at Baseline to Abnormal After 2 Hours Post-treatment33

Adverse events

Collected over Adverse Events were collected from the first dose of study drug administration until the final study visit (60 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OC- 01 (Varenicline) Nasal Spray 0.12 mg0/21 (0%)0/21 (0%)13/21 (61.9%)
Varenicline Oral Tablet 1 mg0/22 (0%)0/22 (0%)9/22 (40.9%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventOC- 01 (Varenicline) Nasal Spray 0.12 mgVarenicline Oral Tablet 1 mg
DizzinessNervous system disorders1/218/22
SneezingRespiratory, thoracic and mediastinal disorders7/210/22
coughRespiratory, thoracic and mediastinal disorders6/210/22
nauseaGastrointestinal disorders0/215/22
vomitingGastrointestinal disorders0/214/22
somnolenceNervous system disorders1/213/22
Nasal pruritusRespiratory, thoracic and mediastinal disorders1/210/22
RhinorrheaRespiratory, thoracic and mediastinal disorders1/210/22
Abdominal pain upperGastrointestinal disorders0/211/22
Dry mouthGastrointestinal disorders0/211/22

Baseline characteristics

Age, Customized
Age, Customized(years)OC-01 (Varenicline Solution) Nasal Spray 0.12 mg Then Varenicline Oral Tablet 1 mgVarenicline Oral Tablet 1 mg Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mgTotal
age39.5 ± 10.644.5 ± 14.042.0 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)OC-01 (Varenicline Solution) Nasal Spray 0.12 mg Then Varenicline Oral Tablet 1 mgVarenicline Oral Tablet 1 mg Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mgTotal
Female3710
Male8412
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OC-01 (Varenicline Solution) Nasal Spray 0.12 mg Then Varenicline Oral Tablet 1 mgVarenicline Oral Tablet 1 mg Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mgTotal
Hispanic or Latino10919
Not Hispanic or Latino123
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)OC-01 (Varenicline Solution) Nasal Spray 0.12 mg Then Varenicline Oral Tablet 1 mgVarenicline Oral Tablet 1 mg Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mgTotal
United States111122
08

Study locations

1 site
  • United States, Miami Florida
    Miami, Florida 33136, United States
09

References and documents

Publications

  • Nau J, Wyatt DJ, Rollema H, Crean CS. A Phase I, Open-label, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability of Intranasal and Oral Varenicline. Clin Ther. 2021 Sep;43(9):1595-1607. doi: 10.1016/j.clinthera.2021.07.020. Epub 2021 Aug 27. PubMed 34456060 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Nov 2019, 2 months.

Results were first posted in May 2022, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2019
First posted
Aug 28, 2019
StartActual
Aug 26, 2019
Primary completionActual
Nov 15, 2019
CompletionActual
Nov 15, 2019
Results first posted
May 23, 2022
Last update
May 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04072146
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Aug 26, 2019
Primary completion
Nov 15, 2019
Completion
Nov 15, 2019
Results posted
May 23, 2022
Last update
May 23, 2022

Study contacts

Jeffrey Nau, PhD
study director · Oyster Point Pharma, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion